Gene Editing and Immunotherapeutic Targeting of ADGRE2/EMR2 to Enable Combinatorial Targeting in Acute Myeloid Leukemia (AML) […]
Publication Type: Poster Presentation
EBMT Annual Meeting – 2023 – Poster Presentation P249
Initial First-In-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplantation (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias […]
Read More… from EBMT Annual Meeting – 2023 – Poster Presentation P249
Keystone Symposia – 2023 – Poster Presentation 3527
Translocation Detection and Quantification Workflow to Characterize CRISPR-Cas Multiplex Edited Hematopoietic Stem and Progenitor Cells (HSPCs) […]
Read More… from Keystone Symposia – 2023 – Poster Presentation 3527
Tandem Meetings – 2023 – Poster Presentation LBA14
Initial First-In-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias […]
Read More… from Tandem Meetings – 2023 – Poster Presentation LBA14
Rocky Conference – 2022 – Poster Presentation 71
A machine learning approach incorporating germline information improves genotyping of CRISPR-Cas9 gene editing events at single cell resolution […]
Read More… from Rocky Conference – 2022 – Poster Presentation 71
ASH – 2022 – Poster Presentation 4587
Efficient Multiplex Gene Editing of CD33 and CLL-1 in Human Hematopoietic Stem Cells Enables the Potential of Next-Generation Transplants for AML Treatment […]
SITC – 2022 – Poster Presentation P334
Functional Validation of Single Domain Antibody-Derived CD33 Specific CAR-T Cells for the Treatment of Acute Myeloid Leukemia […]
ESGCT – 2022 – Poster Presentation P432
Multiplex deletion of myeloid antigens by base editing in human hematopoietic stem and progenitor cells (HSPCs) enables potential for next generation transplant for acute myeloid leukemia (AML) treatment […]
ESGCT – 2022 – Poster Presentation P150
Efficient knockout of both CD33 and CLL-1 by multiplex genome editing of human hematopoietic stem cells enhances the potential of next- generation transplants for acute myeloid leukemia (AML) treatment […]